company background image
TNG

Transgene ENXTPA:TNG Stock Report

Last Price

€1.80

Market Cap

€180.8m

7D

0.9%

1Y

-16.0%

Updated

19 Sep, 2023

Data

Company Financials +

TNG Stock Overview

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.

TNG fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Transgene SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Transgene
Historical stock prices
Current Share Price€1.80
52 Week High€2.55
52 Week Low€1.64
Beta0.75
1 Month Change5.76%
3 Month Change-6.84%
1 Year Change-15.98%
3 Year Change38.52%
5 Year Change-40.56%
Change since IPO-96.01%

Recent News & Updates

Recent updates

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Mar 21
Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 19
Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

Mar 18
Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?

Nov 24
Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?

Apr 16
Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?

What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?

Mar 12
What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?

Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Jan 23
Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Shareholder Returns

TNGFR BiotechsFR Market
7D0.9%-2.8%0.09%
1Y-16.0%-8.6%18.1%

Return vs Industry: TNG underperformed the French Biotechs industry which returned -8% over the past year.

Return vs Market: TNG underperformed the French Market which returned 16.8% over the past year.

Price Volatility

Is TNG's price volatile compared to industry and market?
TNG volatility
TNG Average Weekly Movement3.0%
Biotechs Industry Average Movement5.8%
Market Average Movement3.8%
10% most volatile stocks in FR Market9.5%
10% least volatile stocks in FR Market2.0%

Stable Share Price: TNG is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: TNG's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1979146Alessandro Rivahttps://www.transgene.fr

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.

Transgene SA Fundamentals Summary

How do Transgene's earnings and revenue compare to its market cap?
TNG fundamental statistics
Market Cap€180.81m
Earnings (TTM)-€32.80m
Revenue (TTM)€10.23m

17.7x

P/S Ratio

-5.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TNG income statement (TTM)
Revenue€10.23m
Cost of Revenue€32.17m
Gross Profit-€21.94m
Other Expenses€10.87m
Earnings-€32.80m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

Sep 20, 2023

Earnings per share (EPS)-0.33
Gross Margin-214.42%
Net Profit Margin-320.63%
Debt/Equity Ratio29.3%

How did TNG perform over the long term?

See historical performance and comparison